DELTICOM-AG/MOTO-TYRES.C
31.5.2017 13:28:06 CEST | Business Wire | Press release
Sunshine and leisure time: the ideal combination for motorcyclists. Before you get on your bike and hit the highway in the coming summer months, Moto-tyres.co.uk has already collected a few tips - from bikers to bikers, as the participants were requested to describe their most beautiful motorcycle tours of 2016 for the Moto-tyres.co.uk , Metzeler and Motorrad & Reisen prize competition of last year. The participants travelled many thousands of kilometres across Europe, Norway, Luxembourg, Italy, Portugal and beyond - Moto-tyres.co.uk has listed the best recommendations for travellers as follows.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170531005749/en/
Route 1
The Ardennes, located between Germany, Luxembourg, and Belgium, conceal a true motorcycle paradise: Winding roads, stunning nature and a beautiful reservoir located in the middle of the Obersauer National Park - there is plenty to discover along the 7,000-kilometre route.
Route 2
Through Switzerland and Italy towards Corsica - the 6,000-kilometre route also leads through the unique glacier and lake landscape around the legendary Bernina Pass.
Route 3
Sun, sea and breath-taking views can be admired on Madeira - preferably from the summit of the Pico do Arieiro, the third highest mountain on the so-called "Island of Flowers". Off the beaten tracks, the island round-trip becomes a true biking adventure.
Those bitten by the travel bug will also find the ideal tyres at Moto-tyres.co.uk for the planned trip - from quality premium brands up to high-performance quality tyres. On request, the new tyres can even be delivered directly to one of the many thousands of assembly partners throughout Europe or to touring hotels along the route. Thus, everything is in place for the next trip.
About Moto-tyres.co.uk
Whether you're looking for chopper, sport-touring or scooter tyres: bikers will find everything their heart desires in this renowned online store's range. Accessories such as bike tubes and motor oil complete Delticom's bike range. The two-wheeler tyre specialist's portfolio includes all established premium bike tyre manufacturers such as Metzeler, Pirelli, Continental, Dunlop, Bridgestone and Michelin, as well as renowned quality brands such as Heidenau, Avon, Maxxis and Mitas.
Online store for end users: www.moto-tyres.co.uk
Further online stores in Europe: www.MotorradreifenDirekt.de (DE), www.MotorradreifenDirekt.at (AT), www.MotorradreifenDirekt.ch (CH), www.pneus-moto.fr (FR), www.motorbandenmarkt.nl (NL), www.moto-pneumatici.it (IT), www.neumaticosdemoto.es (ES) and more.
Online store for dealers: www.yourtyres.co.uk
About the company: www.delti.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170531005749/en/
Contact:
insignis Agentur für
Kommunikation GmbH (GPRA)
Henning Jahns
Tel.:
+49-511-132214-14
Fax: +49-511-132214-99
delticom@insignis.de
or
Delticom
AG
Anne Lena Peters
Tel.: +49-511-93634-8909
Fax:
+49-511-93634-8301
anne.lena.peters@delti.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release
Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (
Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release
Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,
BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release
The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu
Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release
Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo
Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release
Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets. “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.” Throughout his career, Dan has held senior leadership roles i
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom